Skip to main content
Prof Doan Ngo
Co-Director
LinkedIn
ORCID
Back to team

Prof Doan Ngo

B.Pharm, PhD, FESC, FCSANZ

Doan is Co-Director of the Newcastle Centre of Excellence in Cardio-Oncology Research, an academic pharmacist and an accomplished basic and translational scientist whose work spans cardio-oncology and cardiometabolic disease. Her expertise is in cardiometabolic pathophysiology, with a focus on obesity, redox stress and vascular biology, and her research has advanced understanding of adipose tissue biology and angiogenesis and their impact on cardiovascular health.

She completed her PhD in Medicine in 2008, developing an animal model of aortic stenosis and demonstrating its prevention with ACE inhibitors, and showing how vitamin D deficiency affects vascular function (work published in the American Journal of Medicine). She then undertook postdoctoral training in Boston, where she established expertise in obesity research and adipose tissue biology and was among the first to characterise the role of the anti-angiogenic factor VEGF-A165b in obesity, with findings published in Circulation, Nature Medicine and Diabetes.

After returning to Australia in 2015 to establish her own research group, Doan relocated to the University of Newcastle in 2017, where she co-led the Cardiometabolic and Vascular Research Group and grew a multidisciplinary team of postdoctoral fellows, research assistants and higher-degree students. Together with Professor Aaron Sverdlov, she established Australia’s first integrated bench-to-bedside cardio-oncology program, linking laboratory research with a clinical outpatient service at Calvary Mater Newcastle that addresses cancer therapy-related cardiotoxicity.

Research interests

  • Cardio-oncology
  • Cardiometabolic disease
  • Obesity, redox stress and vascular biology
  • Adipose tissue biology and angiogenesis
  • Biomarker discovery

Highlights

  • Co-Director, Newcastle Centre of Excellence in Cardio-Oncology Research
  • Pioneering work on VEGF-A165b in obesity, cited more than 200 times
  • Multiple patents, with presentations at CSANZ, ESC and AHA
  • Recognised as an outstanding cardiovascular research leader at CSANZ 2015
  • Research featured by the ABC, The Limbic and news.com.au
  1. Bennetts JD, Mahmud A, Yu J, Ngo DTM, Sverdlov AL, 'Editorial commentary: From signal to care: Artificial intelligence in Cardio-oncology', Trends in Cardiovascular Medicine, 36, 400-401 (2026). https://doi.org/10.1016/j.tcm.2026.03.007
  2. Chen DH, Butel-Simoes L, Bower M, Nolan MT, Kumar SS, Williams TD, Koczwara B, Ell P, Bennetts JD, Nair GR, Lee J, Ramkumar S, Ngo DTM, Sverdlov AL, 'The Current Cardio-Oncology Landscape Across Australia', Current Treatment Options in Oncology, 27 (2026) [C1]. https://doi.org/10.1007/s11864-026-01390-4
  3. Croft A, Kelly C, Chen D, Francis P, Haw TJ, Goggins B, Keely S, Murtha L, Sverdlov A, Ngo D, 'Elucidating sex-based differences in cancer-induced cardiac cachexia.', Journal of Molecular and Cellular Cardiology Plus, 15, 100675-100675 (2026). https://doi.org/10.1016/j.jmccpl.2025.100675
  4. Bennetts JD, Yu J, Williams TD, Van der Westhuizen A, Nordman IIC, Shrestha P, Walker R, Herrmann J, Sverdlov AL, Ngo DTM, 'Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.', Support Care Cancer, 34 (2026). https://doi.org/10.1007/s00520-026-10983-6
  5. Sharma A, McDonagh J, Ngo DTM, De Blasio MJ, Ferguson C, Ritchie RH, 'Assessment of Cardiac Frailty in Preclinical Models of Heart Failure and Ageing - Parallels Between Discovery and the Clinic', Heart Lung and Circulation, 35, 728-744 (2026) [C1]. https://doi.org/10.1016/j.hlc.2026.04.113
  6. Deng Y, Holien J, Ngo D, Naghipour S, Kong A, Lees J, Lim S, 'A Novel Small Molecule Drug To Protect Against Anthracycline-induced Cardiotoxicity', Journal of Molecular and Cellular Cardiology Plus, 15 (2026). https://doi.org/10.1016/j.jmccpl.2025.100529
  7. Valles TE, Shamas M, Hawkins H, Matthews C, Ngo D, Peltekian H, Artin H, Distler MG, DeYoung DZ, Einstein EH, Ginder ND, Koek RJ, Krantz DE, Leuchter MK, Oughli HA, Slan AR, Strouse TB, Tadayonnejad R, Wilke SA, Young AS, Corlier J, Leuchter AF, 'Differential neural responses to rhythmic and patterned TMS protocols: Insights from EEG spectral analysis.', Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 51, 813-821 (2026). https://doi.org/10.1038/s41386-025-02306-w
  8. Bennetts JD, Sverdlov AL, Ngo DT, 'Cardiometabolic perturbations arising from treatment with novel anticancer therapies', Trends in Cardiovascular Medicine, 36, 218-228 (2026) [C1]. https://doi.org/10.1016/j.tcm.2025.10.008
  9. Bennetts JD, Ngo DTM, Cheema B, Hosseini K, Verheyen N, Santner V, Tomasoni D, Sverdlov AL, 'Mavacamten in adolescent obstructive hypertrophic cardiomyopathy: SCOUTing a way forward.', Heart failure reviews, 31 (2026). https://doi.org/10.1007/s10741-026-10655-x
  10. Butel-Simoes LE, Albayati A, Yu J, Quirk T, Sritharan S, French M, Bennetts JD, Ngo DTM, Sverdlov AL, 'Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding', Journal of Thrombosis and Thrombolysis, 59, 393-410 (2026) [C1]. https://doi.org/10.1007/s11239-025-03151-w
  11. Butel-Simoes LE, Bennetts JD, Croft A, Williams TD, Janowski W, Martin J, Lynam J, Ngo DTM, Sverdlov AL, 'Integrated Cardio-oncology Service', Cardiac Failure Review, 12 (2026) [C1]. https://doi.org/10.15420/cfr.2025.44
  12. Bennetts JD, Robson C, Weismantel-Savage A, Mani J, Yu J, Robson L, Collins NJ, Williams TD, Sverdlov AL, Ngo DTM, 'Evaluation of a Nurse-Pharmacist Post-Discharge Telehealth Model of Care for People With Heart Failure', Heart Lung and Circulation, 35, 906-917 (2026) [C1]. https://doi.org/10.1016/j.hlc.2025.12.025
  13. Joshua D Bennetts, Aaron L Sverdlov, Doan TM Ngo. Cardiometabolic Perturbations Arising from Treatment with Novel Anticancer Therapies. Trends in Cardiovascular Medicine 2025. https://doi.org/10.1016/j.tcm.2025.10.008
  14. Lloyd E Butel-Simoes, Ammar Albayati, Jie Yu, Thomas Quirk, Shanathan Sritharan, Matthew French, Joshua D Bennetts, Doan TM Ngo, Aaron L Sverdlov. Tyrosine kinase inhibitors-balancing the haemostatic scales: a review of associated thrombosis and bleeding. Journal of Thrombosis and Thrombolysis 2025.  https://doi.org/10.1007/s11239-025-03151-w
  15. Chen D, Croft AJ, Haw TJ, Kelly C, Balachandran L, Sverdlov AL#, Ngo DTM#. Anti-cancer agent Olaparib ameliorates Doxorubicin-induced Cardiotoxicity in vitro and in vivo. J Mol Cell Cardiol 2025; 206:114-126. https://doi.org/10.1016/j.yjmcc.2025.07.015. PMID: 40712701
  16. Bennetts JD, Williams TD, Beavers GJ, Moore HN, Robson C, Warner T, Dent S, Sverdlov AL#, Ngo DTM#. The Cardio-Oncology Multidisciplinary Team: Beyond the Basics. Cardio-Oncology 2025; 11, 69. https://doi.org/10.1186/s40959-025-00369-8. PMID: 40713756
  17. Kelly C, Kiltschewskij D, Leong AJW, Haw TJ, Croft AJ, Balachandran L, Chen D, Bond DR, Lee HJ, Cairns M, Sverdlov AL#, Ngo DTM#. Identifying common pathways for Doxorubicin and Carfilzomib-induced cardiotoxicities: Transcriptomic and epigenetic profiling. Sci Rep 2025; 15(1):4395. doi: 10.1038/s41598-025-87442-5. PMID: 39910168
  18. Butel-Simoes LE, Ngo DTM, Sverdlov AL. Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score. Eur Heart J 2025; 46(3):285-287. doi: 10.1093/eurheartj/ehae624. PMID: 39680373
  19. Sritharan S, Kelly C, Sverdlov A, Boyle A, Ngo DTM, Davies A, Lim J, Ray M, Collins N. Novel Biomarkers of Cerebrovascular Function in Adult Congenital Heart Disease. JACC Adv 2025; 4 (1) 101439.
  20. Alshehri D, Noman N, Chiong R, Miah SJ, Sverdlov AL, Ngo DT. Factors Influencing the Adoption of Internet of Medical Things for Remote Patient Monitoring: A Systematic Literature Review. Comput Biol Med 2025; 192(Pt B):110142. doi: 10.1016/j.compbiomed.2025.110142. PMID: 40375424
  21. Mecinaj A, Vinje-Jakobsen V, Ngo DTM, Sverdlov AL, Myhre PL. The SARAH trial: More evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev 2025; 30(3):627-631. doi: 10.1007/s10741-025-10495-1. PMID: 3996055
  22. Nolan MT, Ngo DTM, Sverdlov AL. How to build an actionable narrative for Cardio-Oncology. Trends Cardiovasc Med 2025; 35(1):32-33. https://doi.org/10.1016/j.tcm.2024.06.001. PMID: 38950663
  23. Bennetts J, White J, Croft H, Cooper J, McIvor D, Eadie N, Appay M, Sverdlov AL, Ngo DTM. Pharmacist-Led Medication Management Services: A Qualitative Exploration of Transition-of-Care Cardiovascular Disease Patient Experiences. BMJ Open 2024 May 22;14(5):e082228. doi: 10.1136/bmjopen-2023-082228.
  24. Henry M Gomez, Tatt J Haw, Dusan Ilic, Peter Robinson, Chantal Donovan, Amanda J Croft, Kanth S Vanka, Ellen Small, Olivia R Carroll, Richard Y Kim, Jemma R Mayall, Tesfalidet Beyene, Thava Palanisami, Doan TM Ngo, Graeme R Zosky, Elizabeth G Holliday, Megan E Jensen, Vanessa M McDonald, Vanessa E Murphy, Peter Gibson, Jay C Horvat. Landscape fire smoke airway exposure impairs respiratory and cardiac function and worsens experimental asthma. Journal of Allergy and Clinical Immunology. Volume 154, Issue 1, July 2024, Pages 209-221.e6
  25. Croft AJ, Kelly C, Chen D, Murtha LA, Haw TJ, Balachandran L, Boyle AJ, Sverdlov AL#, Ngo DTM#. Sex-based differences in short and longer-term diet-induced metabolic heart disease. Am J Physiol Heart Circ Physiol 2024; doi: 10.1152/ajpheart.00467.2023. PMID: 38363215.
  26. Singleton AC, Redfern J, Diaz A, Koczwara B, Nicholls SJ, Negishi K, La Gerche A, Playford D, Conyers R, Cehic DA, Garvey G, Williams T, Hunt L, Doyle K, Figtree G, Ngo DTM#, Sverdlov AL#. Integrating cardio-oncology across the research pipeline, policy, and practice in Australia - an ACvA perspective. Heart Lung Circ 2024; https://doi.org/10.1016/j.hlc.2024.01.011. PMID: 38336544
  27. Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, Sverdlov AL#, Ngo DTM#. Cancer therapies and cardiomyocyte viability: which drugs are directly cardiotoxic? Heart Lung Circ 2024; https://doi.org/10.1016/j.hlc.2024.01.013. PMID: 38365500
  28. Collins NJ, Ngo DTM, Sverdlov AL. New cimlanod trial provides insights into mechanistic effects of vasodilators in heart failure. Eur J Heart Fail 2024; 26(1):152-154. doi: 10.1002/ejhf.3110. PMID: 38124440
  29. Ray M*, Butel-Simoes LE*, Lombard JM, Nordman IIC, van der Westhuizen A, Collins NJ, Ngo DTM#, Sverdlov AL#. Women’s Cardiovascular Health - The Cardio-Oncologic Jigsaw. Climacteric 2024; 27(1):60-67. http://dx.doi.org/10.1080/13697137.2023.2286382. PMID: 38073542
  30. Williams T, Ngo DTM, Sverdlov AL. Examining real world quality of care for Australia’s First Peoples presenting with chest pain. Lancet Reg Health West Pac 2023; 38:100869; https://doi.org/10.1016/j.lanwpc.2023.100869. PMID: 37529487
  31. Murtha LA, Hardy SA, Mabotuwana NS, Bigland MJ, Bailey T, Raguram K, Liu S, Ngo DT, Sverdlov AL, Tomin T, Birner-Gruenberger R, Hume RD, Iismaa SE, Humphreys D, Patrick R, Chong JJH, Lee RJ, Harvey RP, Graham RM, Rainer PP, Boyle AJ. Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction. Sci Rep 2023; 13(1):14995. doi: 10.1038/s41598-023-41894-9. PMID: 36939661
  32. Kelly C, Chu M, Untaru R, Assadi-Khansari B, Chen D, Croft AJ, Horowitz JD, Boyle AJ, Sverdlov AL#, Ngo DTM#. Association of circulating plasma Secreted Frizzled-related protein 5 (Sfrp5) levels with cardiac function. J Cardiovasc Dev Dis 2023; 10(7), 274; https://doi.org/10.3390/jcdd10070274. PMID: 37504530
  33. Croft AJ, Kelly C, Chen D, Haw TJ, Sverdlov AL#, Ngo DTM#. Overexpression of mitochondrial catalase within adipose tissue does not confer systemic metabolic protection against diet-induced obesity. Antioxidants 2023; 12(5), 1137 IF =7.7 https://doi.org/10.3390/antiox12051137
  34. Butel-Simoes L*, Haw TJ*, Williams T*, Sritharan S, Gadre P, Herrmann SM, Herrmann J, Ngo DTM#, Sverdlov AL#. Established and Emerging Cancer Therapies and Cardiovascular System: focus on hypertension - mechanisms and mitigation. Hypertension 2023; 80(4):685-710. doi: 10.1161/HYPERTENSIONAHA.122.17947. PMID: 36756872
  35. Williams TD, Kaur A, Warner T, Aslam M, Clark V, Walker R, Ngo DT#, Sverdlov AL#. Cardiovascular outcomes of cancer patients in rural Australia. Front Cardiovasc Med 2023; 10:1144240. doi: 10.3389/fcvm.2023.1144240. PMID: 37180785 IF =6.0
  36. Chen D, Untaru R, Stavropoulou G, Assadi-Khansari B, Kelly C, Croft AJ, Sugito S, Collins NJ, Sverdlov AL#, Ngo DTM#. Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). J Clin Med 2023; 12(8):2790. doi: 10.3390/jcm12082790. PMID: 37109127 IF = 3.3
  37. McGee M, Shephard L, Sugito S, Baker D, Brienesse S, Al-Omary M, Nathan-Marsh R, Ngo DTM, Oakley P, Boyle AJ, Garvey G, Sverdlov AL. Mind the Gap, Aboriginal and Torres Strait Islander Cardiovascular Health: A Narrative Review. Heart Lung Circ 2023; 32(2):136-142. doi: 10.1016/j.hlc.2022.09.017. PMID: 36336616
  38. Nolan MT, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon AR, Negishi K, Ngo DTM, Thomas L, Vardy J, Sverdlov AL. First ESC Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty. Heart Lung Circ Volume 31, Issue 12, December 2022, Pages 1563-1567 https://doi.org/10.1016/j.hlc.2022.11.003
  39. Deng Y, Ngo DTM, Holien JK, Lees JG, Lim SY. Mitochondrial dynamin-related protein Drp1: A new player in cardio-oncology. Current Oncology Reports 2022:24(12):1751-63. Doi: 10.1007/s11912-022-01333-w
  40. White J, Byles J, Williams T, Untaru R, Ngo DTM, Sverdlov AL. Early access to a cardio-oncology clinic in an Australian context: A qualitative exploration of patient experiences. Cardio-Oncology 2022; 8(1):14. doi: 10.1186/s40959-022-00140-3. PMID: 35945637.
  41. McGee M, Shephard L, Sugito S, Baker D, Brienesse S, Al-Omary M, Nathan-Marsh R, Ngo DTM, Oakley P, Boyle AJ, Garvey G, Sverdlov AL. Mind the Gap, Aboriginal and Torres Strait Islander Cardiovascular Health: A Narrative Review. Heart Lung Circ 2022; S1443-9506(22)01130-1. doi: 10.1016/j.hlc.2022.09.017.
  42. Al-Omary MS, Majeed T, Al-Khalil H, Sugito S, Clapham M, Ngo DTM, Attia J, Boyle AJ, Sverdlov AL. Patient characteristics, short and long-term outcomes after incident heart failure admissions in a regional Australian setting. Open Heart 2022; 9(1):e001897 DOI: 10.1136/openhrt-2021-001897
  43. Chen D*, Kelly C*, Haw TJ*, Lombard JM, Nordman IIC, Croft AJ, Ngo DTM#, Sverdlov AL#. Heart failure in breast cancer survivors: focus on early detection and novel biomarkers. Curr Heart Fail Rep 2021; DOI: 10.1007/s11897-021-00535-w
  44. Cehic DA, Sverdlov AL, Koczwara B, Emery J, Ngo DTM, Thornton-Benko E. The Importance of Primary Care in CardioOncology. Curr Treat Options Oncol 2021 Dec;18(6):362-377 accepted.
  45. Ell P, Martin J, Cehic DA, Ngo DTM, Sverdlov AL. Cardiotoxicity of Radiation Therapy: Mechanisms, Management and Mitigation. Curr Treat Options Oncol (2021) 22: 70 DOI 10.1007/s11864-021-00868-7
  46. McGee M, Sugito S, Al-Omary MS, Hartnett D, Senanayake T, Hales K, Majeed T, Ngo DTM, Oakley P, Leitch JW, Sverdlov AL, Boyle AJ. Heart Failure Outcomes in Aboriginal and Torres Strait Islander Peoples in the Hunter New England Region of New South Wales. Int J Cardiol 2021; 334:65-71. doi: 10.1016/j.ijcard.2021.04.001.=
  47. Doan Ngo *, Trent William, Sophie Horder, Leonard Kritharides, Janette Vardy, Hiren Mandaliya, Ina Nordman, James Lynam, Tony Bonaventura, Aaron Sverdlov *. Factors associated with adverse cardiovascular events in cancer patients treated with Bevacizumab. Journal of Clinical Medicine. J Clin Med 2020; 9(8), 2664; https://doi.org/10.3390/jcm9082664. * Joint corresponding authors.
  48. Chandra Kirana,#, Eric Smith#, Doan T Ngo#, Markus I Trochsler, Peter J Hewett, Richard Stubbs, Jennifer E Hardingham, Guy J Maddern, Ehud Hauben. High preoperative levels of circulating SFRP5 predict better prognosis in colorectal cancer patients. Future Oncology 2020; 16(31): 2499-2509. # Co-1st authors. https://doi.org/10.2217/fon-2020-0356
  49. Untaru R, Chen D, Kelly C, May A, Collins NJ, Leitch J, Attia JR, Proietto AM, Boyle AJ, Sverdlov AL, Ngo DTM. Suboptimal Use of Cardioprotective Medications in Patients with a History of Cancer. JACC: CardioOncology 2020; 2(2): 312-315. doi: 10.1016/j.jaccao.2020.05.010
  50. Saifei Liu, Doan Ngo, Yuliy Chirkov, Jeanette Stansborough, Cher‐Rin Chong, John D Horowitz. Prolonged suppression of the anti‐oxidant/anti‐inflammatory effects of BNP post‐Takotsubo syndrome. ESC Heart Failure 2020; 7(5): 2250-2257. https://doi.org/10.1002/ehf2.12729.
  51. Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G. The nexus of cancer and cardiovascular disease for Australia’s First Peoples. JCO Glob Oncol 2020; 6:115-119.
  52. Croft AJ, Ngo DTM, Sverdlov AL. Anthracycline-induced cardiotoxicity: Time to focus on cardioprotection again. Heart Lung Circ 2019; 28(10):1454-1456.
  53. Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ. Ibrutinib Related Atrial Fibrillation - A Single Centre Australian Experience. Asia Pac J Clin Oncol 2019; 15(5):e187-e190.
  54. Doan TM Ngo*, Aaron L Sverdlov*, Shakun Karki, Donia Macartney-Coxson, Richard S Stubbs, Melissa G Farb, Brian Carmine, Donald T Hess, Wilson S Colucci, Noyan Gokce. Oxidative Modifications of Mitochondrial Complex II are associated with insulin resistance of visceral fat in obesity. Am J Physiol Endocrinol Metab 2019; 316(2):E168-E177. (IF: 4.0) (Q1)
  55. Figtree GA, Ngo DT, Bubb K. Testosterone to estradiol ratio and plaque inflammation- mechanistic insights and biomarker potential? Cardiovascular Research. 2019 Feb 1;115(2):255-257 (IF: 8.2) (Q1)
  56. Murtha LA*, Morten M*, Schuliga MJ*, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, Ngo DTM, Sverdlov AL, Knight DA, Boyle AJ. The role of pathological aging in cardiac and pulmonary fibrosis. Aging Dis 2019; 10(1): DOI: 10.14336/AD.2018.0601 (IF: 5.4) (Q1)
  57. Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, Licari G, Raman B, Kelly DJ, Zhang Y, Waddingham MT, Ngo DT, Bate AP, Chua SJ, Frenneaux MP, Horowitz JD. Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. JACC Basic Transl Sci. 2018; 18;3(2):213-226 (IF 4.8) (Q1)
  58. Amaraskera A, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, Sverdlov AL, Horowitz JD, Ngo DT. Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults. PLOS ONE 2017; 12(5):e0174435. (IF: 3.1) (Q1)
  59. Karki S, Ngo DT, Farb MG, Park SY, Saggese S, Hamburg NM, Hess DT, Carmine B, Walsh KX, Gokce N. WNT5A Regulates Adipose Tissue Angiogenesis via Anti-Angiogenic VEGFA165b in Obese Humans. American Journal of Physiology - Heart and circulatory physiology 2017:ajpheart.00776.2016. doi: 10.1152/ajpheart.00776.2016 (IF 3.6)
  60. Canavese M, Ngo DT, Maddern GJ, Hardingham JE, PriceTJ, Hauben E. Biology and Therapeutic Implications of VEGF-A Splice Isoforms and Single-Nucleotide Polymorphisms in Colorectal Cancer. Int J Cancer 2017; 140(10):2183-2191 (IF: 5.1) (Q1)
  61. Chen D, Procter NE, Goh V, Liu S, Chua SJ, Assadi-Khansari B, Stewart S, Horowitz JD, Sverdlov AL, Ngo DT. New onset atrial fibrillation is associated with elevated Galectin-3 levels. Int J Cardiol 2016; 223:48-49 (IF: 4.6) (Q1)
  62. Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT. Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients. Diabetes Metab 2016 Nov;42(5):378-381. doi: 10.1016/j.diabet.2016.05.002 (IF: 4.7) (Q1)
  63. Sverdlov AL, Figtree GA, Horowitz JD, Ngo DT. Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome. Mediators of Inflammation 2016. 2016;2016:8254590 (IF: 3.4)
  64. Procter NE, Ball J, Ngo DT, Isenberg JS, Hylek EM, Chirkov YY, Stewart S, Horowitz JD. Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. J Geriatr Cardiol 2016;13(3):202-8 (IF: 2.5) (Q3)
  65. Procter NE, Ball J, Ngo DT, Chirkov YY, Isenberg JS, Hylek EM, Stewart S, Horowitz JD. Platelet hyperaggregability in patients with atrial fibrillation : Evidence of a background proinflammatory milieu. Herz 2016; 41(1):57-62. (IF: 1.0)
  66. Ngo DT, Gokce N. Epicardial adipose tissue: a benign consequence of obesity? Circulation: Cardiovasc Imaging. 2015 Mar;8(3). pii: e003156 (IF: 5.8) (Q1) (rank: 12/124)
  67. Horowitz JD, Chong CR, Ngo DT, Sverdlov AL. Effects of acute hyperglycemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down? J Thorac Dis 2015; 7(12): E607-11 (IF:2.4) (Q3) (rank: 42/58)
  68. Procter NE, Ball J, Heresztyn T, Nooney VB, Liu S, Chong CR, Ngo DT, Isenberg JS, Chirkov YY, Stewart S, Horowitz JD. Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. Am J Cardiovasc Dis 2015; 5(2):101-9. (IF:2.2)
  69. Karki S, Farb M, Ngo DT, Myers S, Puri V, Hamburg N, Carmine B, Hess D, Gokce N. Forkhead Box O-1 modulation improves endothelial insulin resistance in human obesity. Arteriosclerosis, Thrombosis, and Vascular Biology 2015. 35(6):1498-506 (IF: 6.6) (Q1) (rank: 4/63)
  70. Liu S, Ngo DT, Chong CR, Amarasekera A, Procter NEK, Licari G, Dautov R, Stewart S, Chirkov YY, Horowitz JD. Suppression of the neutrophil superoxide generation by BNP is attenuated in acute heart failure: a case for "BNP resistance". European Journal of Heart Failure 2015; 17(5):475-83 (IF: 11.6) (Q1) (rank: 17/124)
  71. Chong CR, Liu S, Licari G, Heresztyn T, Chirkov YY, Ngo DT, Horowitz JD. Reversal of hyperglycemia: effects on nitric oxide signalling. Am J Med 2015; 128(4):427-30. (IF: 4.8) (Q1) (rank: 14/155)
  72. Fuster JJ, Zuriaga M, Ngo DTM, Farb MG, Aprahamian T, Yamaguchi TP, Gokce N, Walsh K. Non-canonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction. Diabetes 2015; 64(4):1235-48. (IF: 7.7) (Q1) (rank: 9/133)
  73. Procter NEK, Ball J, Liu S, Hurst N, Nooney VB, Goh V, Stafford I, Heresztyn T, Carrington M, Ngo DTM, Hylek EM, Isenberg JS, Chirkov YY, Stewart S, Horowitz JD. Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. Int J Cardiol 2015;179:160-5. (IF: 4.6) (Q1) (rank: 20/124)
  74. Kikuchi R, Nakamura K, MacLauchlan S, Ngo DTM, Shimizu I, Fuster JJ , Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi TP, Matsushita T, Murohara T, Gokce N, Bates DO, Hamburg NM, Walsh K. An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nature Medicine 2014; 20(12):1464-71 (IF: 36.1) (Q1) (rank: 1/289)
  75. Ngo DTM, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, La Valley MP, Hamburg NM, Vita JA, Hess DT, Walsh K, Gokce N. Anti-angiogenic actions of VEGF-A165b, an inhibitory isoform of VEGF-A, in human obesity. Circulation 2014;130(13):1072-80. (IF: 23.6) (Q1) (rank: 2/124)
  76. Liu S, Ngo DTM, Chirkov YY, Stewart S, Horowitz JD. BNP suppression of neutrophil superoxide generation: mechanistic studies in normal subjects. Clinical and Experimental Pharmacology Physiology 2014; 41(10):739-743(IF: 2.0) (Q3) (rank: 154/255)
  77. Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD. Aging of the nitric oxide system: Are we as old as our NO? J Am Heart Assoc 2014; 3:e000973 doi: 10.1161/JAHA.114.000973. (IF: 5.1) (Q1) (rank: 18/124)
  78. Chong CR, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, Sverdlov AL, Chirkov YY, Horowitz JD. Thioredoxin-interacting protein: Pathophysiology and pharmacotherapeutics in cardiovascular diseases and diabetes. Cardiovascular Drugs and Therapy 2014; 28(4): 347:360 (IF: 3.2) (Q2) (rank: 42/124)
  79. Karki S, Ngo DTM, Bigornia S, Farb MG, Gokce N. Insulin resistance: A key therapeutic target for cardiovascular risk reduction in obese patients? Expert Review of Endocrinology & Metabolism 2014; 9(2):93-95. (IF: 2.0)
  80. Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, Kemp-Harper BK, Horowitz JD, Chirkov YY. The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide: Biology and Chemistry 2013; 35:72-78. (IF: 3.3) (Q2) (rank: 87/289)
  81. Sverdlov AL, Chan WPA, Procter NE, Chirkov YY, Ngo DT, Horowitz JD. Reciprocal regulation of NO signalling and TxNIP in humans: Impact of aging and ramipril therapy. Int J Cardiol 2013; 168(5):4624-30. (IF: 4.6) (Q1) (20/124)
  82. Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, Chirkov YY, Tsikas D, Frenneaux MP, Horowitz JD. Enhanced NO signalling in patients with Tako-Tsubo cardiomyopathy: short-term pain, long-term pain? Cardiovascular Drugs and Therapy 2013; 27(6):541-7. (IF: 4.0)
  83. Chan WP, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, Chirkov YY, Horowitz JD. Premature ageing of cardiovascular/platelet function in polycystic ovarian syndrome. Am J Med 2013; 126(7): 640.e1-7. (IF: 5.3) (Q1) (rank: 14/155)
  84. Farb MG, Tiwari S, Karki S, Ngo DT, Carmine B, Hess DT, Zuriaga MA, Walsh K, Fetterman JL, Hamburg NM, Vita JA, Apovian CM, Gokce N. Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity. Obesity (Silver Spring) 2014; 22:349-55. (IF: 4.4) (Q1) (rank: 18/80)
  85. Maher A, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez B, Feelisch M, O'Sullivan A, Christopoulos A, Sverdlov A, Ngo D, Dautov R, James P, Horowitz J, Frenneaux M. Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite. Br J Pharmacol 2013; 169(3):659-70. (IF: 7.7)
  86. Ngo DTM, Horowitz JD, Sverdlov AL. Heart failure - a corin deficient state? Hypertension 2013; 61:284-5 (IF: 7.0) (Q1) (rank: 3/63)
  87. Sverdlov AL*, Ngo DTM*, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD. Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. Eur Heart J 2012; 33(19):2419-25. (IF: 22.7) (Q1) (rank: 3/124) *Denotes joint first author.
  88. Ngo DT*, Sverdlov AL*, Chirkov YY, Horowitz JD. Prevention of aortic valve stenosis: a realistic therapeutic target? Pharmacol Ther 2012; 135(1): 78-93. (IF: 11.1) (Q1) (rank: 6/255). *Denotes joint first author.
  89. Zhang J, Youn J, Kim A, Ramirez R, Gao L, Ngo D, Scovotti J, Mahajan A and Cai HL. NOX4-dependent Hydrogen Peroxide Overproduction in Human Atrial Fibrillation and HL-1 Atrial Cells: Relationship to Hypertension. Front Physiol. 2012; 3:140. (IF: 4.1) (Q1) (rank: 14/83)
  90. Sverdlov AL, Ngo DT, Horowitz JD. Redefining the natural history of calcific aortic stenosis: lessons from Laennec. J Intern Med 2012; 271(6):569-72. (IF: 7.8) (Q1) (rank: 10/155)
  91. Sverdlov AL, Ngo DT, Horowitz JD. Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation. Am J Cardiovasc Dis 2012; 2(1):43-9. (IF: 2.0)
  92. Sverdlov AL, Ngo DT, Chapman MJ, Akbar Ali O, Chirkov YY, Horowitz JD. The pathogenesis of aortic stenosis: not just a matter of wear and tear. Am J Cardiovasc Dis 2011; 1 (2):185-199. (IF: 2.0)
  93. Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, O’Loughlin PD, Morris HA, Chirkov YY, Norman RJ, Horowitz JD. Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide: Biology and Chemistry 2011; 25(3):326-30. (IF: 3.3)
  94. Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry 2011; 25:41-46. (IF: 3.3)
  95. Ling L, Chik W, Averbuj P, Pati P, Sverdlov A, Ngo D, Morris RG, Sallustio BC, Horowitz JD. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state perhexiline. Ther Drug Monit 2011; 33(2):251-6. (IF: 2.0)
  96. Ngo DTM, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, Kelly DJ, Weedon H, Smith MD, Kennedy JA, Horowitz JD. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol 2011; 162 (3): 722-32. (IF: 7.7)
  97. Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD. Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects. Int J Cardiol 2011; 150: 33-8. (IF: 4.6) (Q1) (rank: 20/124)
  98. Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate ADMA and CRP concentrations? Am J Med 2010; 123:335-341. (IF: 5.6) (Q1) (rank: 14/155)
  99. Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD. Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine. Pharmacol Res 2009; 60(6):503-7. (IF: 4.8) (Q1) (rank: 27/255)
  100. Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Determinants of occurrence of aortic sclerosis in an aging population. J Am Coll Cardiol Img 2009; 2:919-927. (IF: 20.6) (Q1) (rank: 1/124)
  101. Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, Nightingale AK, Rosenkranz AC, Smith MD, Chirkov YY, Kennedy JA, Horowitz JD. Vitamin D2 supplementation induces development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol 2008; 590:290-6. (IF: 3.2) (Q2) (rank: 92/255)
  102. Ngo DT, Herestyzn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide: Biology and Chemistry 2007;16: 197-201. (IF: 3.8) (Q2) (rank: 87/289)
  103. Ngo DT, Wuttke RD, Turner S, Marwick TH, Horowitz JD. Quantitative assessment of aortic sclerosis using ultrasonic backscatter. J Am Soc Echocardiogr 2004;17: 1123-1130. (IF: 5.5) (Q1) (rank: 30/124)